About Atopix Therapeutics
Atopix Therapeutics is a company based in Abingdon (United Kingdom) founded in 2012 was acquired by Chiesi Pharmaceuticals in November 2016.. Atopix Therapeutics has raised $5.96 million across 4 funding rounds from investors including SVB, Bessemer Venture Partners and Chiesi Pharmaceuticals. The company has 6 employees as of December 31, 2017. Atopix Therapeutics offers products and services including Timapiprant, ATX2417, and CAR-T Cell Production. Atopix Therapeutics operates in a competitive market with competitors including Celgene, Poseida Therapeutics, Juno Therapeutics, Revance Therapeutics and TScan Therapeutics, among others.
- Headquarter Abingdon, United Kingdom
- Employees 6 as on 31 Dec, 2017
-
Sectors
Healthcare
-
Email
***********
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Atopix Therapeutics Limited
- Date of Incorporation 10 Oct, 2012
- Jurisdiction LONDON
-
Annual Revenue
$584.19 K (USD)0as on Dec 31, 2017
-
Net Profit
$763 K (USD)117as on Dec 31, 2017
-
EBITDA
-
Total Equity Funding
$5.96 M (USD)
in 4 rounds
-
Latest Funding Round
$5.07 M (USD), Debt – Conventional
Jun 17, 2015
-
Investors
SVB
& 8 more
-
Employee Count
6
as on Dec 31, 2017
-
Acquired by
Chiesi Pharmaceuticals
(Nov 17, 2016)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Atopix Therapeutics
Atopix Therapeutics offers a comprehensive portfolio of products and services, including Timapiprant, ATX2417, and CAR-T Cell Production. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.
CRTH2 antagonist for treating severe asthma and allergies.
CRTH2 antagonist targeting allergic conditions like rhinitis.
Manufactures CAR-T cells using bioreactors for large-scale production.
Funding Insights of Atopix Therapeutics
Atopix Therapeutics has successfully raised a total of $5.96M across 4 strategic funding rounds. The most recent funding activity was a Debt – Conventional round of $5.07 million completed in June 2015. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 4
- Last Round Debt – Conventional — $5.1M
-
First Round
First Round
(01 Jan 2013)
- Investors Count 8
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jun, 2015 | Amount | Debt – Conventional - Atopix Therapeutics | Valuation |
investors |
|
| Oct, 2014 | Amount | Series A - Atopix Therapeutics | Valuation |
investors |
|
| May, 2013 | Amount | Grant - Atopix Therapeutics | Valuation |
investors |
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in Atopix Therapeutics
Atopix Therapeutics has secured backing from 9 investors, including institutional and venture fund investors. Prominent investors backing the company include SVB, Bessemer Venture Partners and Chiesi Pharmaceuticals. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
A biotechnology venture capital firm investing in innovative science.
|
Founded Year | Domain | Location | |
|
Investments are made in early-stage healthcare startups.
|
Founded Year | Domain | Location | |
|
Venture capital investments and support for entrepreneurs in technology and innovation sectors.
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Atopix Therapeutics
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - Atopix Therapeutics
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Atopix Therapeutics Comparisons
Competitors of Atopix Therapeutics
Atopix Therapeutics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Celgene, Poseida Therapeutics, Juno Therapeutics, Revance Therapeutics and TScan Therapeutics, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Therapies for cancer and inflammatory diseases are developed.
|
|
| domain | founded_year | HQ Location |
Developer of gene therapies for treating cancer and liver orphan disease by using gene editing technologies
|
|
| domain | founded_year | HQ Location |
CAR T-cell and T-cell receptor immunotherapies for cancer are developed.
|
|
| domain | founded_year | HQ Location |
Neurotoxin products for aesthetic and therapeutic skin treatments are developed.
|
|
| domain | founded_year | HQ Location |
T cell-based treatments for immunological and oncological disorders are developed.
|
|
| domain | founded_year | HQ Location |
T-cell-based therapies for autoimmune and degenerative diseases are developed.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Frequently Asked Questions about Atopix Therapeutics
When was Atopix Therapeutics founded?
Atopix Therapeutics was founded in 2012 and raised its 1st funding round 1 year after it was founded.
Where is Atopix Therapeutics located?
Atopix Therapeutics is headquartered in Abingdon, United Kingdom. It is registered at Abingdon, Oxfordshire, United Kingdom.
Who is the current CEO of Atopix Therapeutics?
Ugo Di Francesco is the current CEO of Atopix Therapeutics.
Is Atopix Therapeutics a funded company?
Atopix Therapeutics is a funded company, having raised a total of $5.96M across 4 funding rounds to date. The company's 1st funding round was a Grant of $2.56M, raised on Jan 01, 2013.
How many employees does Atopix Therapeutics have?
As of Dec 31, 2017, the latest employee count at Atopix Therapeutics is 6.
What is the annual revenue of Atopix Therapeutics?
Annual revenue of Atopix Therapeutics is $584.19K as on Dec 31, 2017.
What does Atopix Therapeutics do?
Atopix Therapeutics is a clinical-stage company developing medicines to treat a range of disease indications including atopic dermatitis and severe asthma. It is developing a class of oral anti Th-2 therapies called CRTH2 antagonists which were acquired from Oxagen. Its lead candidate OC459 is currently being studied in Phase 2 clinical trial for moderate-to-severe atopic dermatitis. It is also assessing the safety and pharmacokinetic profile of its backup molecule ATX2417 in a Phase I study. Its pipeline also has topical candidates that can be formulated for treatment of a number of severe allergic conditions including eye disease.
Who are the top competitors of Atopix Therapeutics?
Atopix Therapeutics's top competitors include Revance Therapeutics, Juno Therapeutics and ArsenalBio.
What products or services does Atopix Therapeutics offer?
Atopix Therapeutics offers Timapiprant, ATX2417, and CAR-T Cell Production.
Who are Atopix Therapeutics's investors?
Atopix Therapeutics has 9 investors. Key investors include SVB, Bessemer Venture Partners, Chiesi Pharmaceuticals, Medical Research Council, and SR One.